Human Metabolome Technologies (TSE:6090) Change In Receivables: 円0 Mil (TTM As of Mar. 2026)

Author:

Vera Yuan

Director of Data and Quant Analytics at GuruFocus

Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.

View Profile →

Reviewed by:

Charlie Tian

Founder & CEO of GuruFocus

Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

View Profile →

Human Metabolome Technologies Inc TSE:6090

62 GF Score

Price 円608.00

GF Value 円695.84

Valuation Modestly Undervalued

3 Warning Signs

View Full Analysis

Start Your Free 7-Day GuruFocus Premium Trial

Unlock 30-Y financials, GF Score, and 150+ pro screeners →

What is Human Metabolome Technologies Change In Receivables?

Human Metabolome Technologies TSE:6090 62 Change In Receivables is 円0 Mil as of Mar. 2026. GuruFocus rates TSE:6090 with a GF Score™ of 62/100 and a GF Value™ of 円695.84 (Modestly Undervalued). The stock has 3 warning signs investors should review.

Human Metabolome Technologies's change in receivables for the quarter that ended in Mar. 2026 was 円0 Mil. It means Human Metabolome Technologies's Accounts Receivable stayed the same from Dec. 2025 to Mar. 2026 .

Human Metabolome Technologies's change in receivables for the fiscal year that ended in Jun. 2025 was 円40 Mil. It means Human Metabolome Technologies's Accounts Receivable declined by 円40 Mil from Jun. 2024 to Jun. 2025 .

Human Metabolome Technologies's Accounts Receivable for the quarter that ended in Mar. 2026 was 円290 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Human Metabolome Technologies's Days Sales Outstanding for the three months ended in Mar. 2026 was 59.09.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Human Metabolome Technologies's liquidation value for the three months ended in Mar. 2026 was 円1,296 Mil.

Try GuruFocus Premium free for 7 days

Unlock GF Score, GF Value, 30-Y financials, and pro screeners.

Get Started →

Human Metabolome Technologies (TSE:6090) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Human Metabolome Technologies's Days Sales Outstanding for the quarter that ended in Mar. 2026 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	290.074	/	447.976	*	91
=	59.09

2. In Ben Graham's calculation of liquidation value, Human Metabolome Technologies's accounts receivable are only considered to be worth 75% of book value:

Human Metabolome Technologies's liquidation value for the quarter that ended in Mar. 2026 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	1456.118	-	402.908	+	0.75 * 290.074	+	0.5 * 50.759
=	1,296

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Human Metabolome Technologies Change In Receivables Related Terms

Human Metabolome Technologies Change In Receivables Historical Data

* Premium members only.

The historical data trend for Human Metabolome Technologies's Change In Receivables can be seen below:

Human Metabolome Technologies Change In Receivables Chart

Human Metabolome Technologies Annual Data

Trend

Mar16

Mar17

Mar18

Mar19

Jun20

Jun21

Jun22

Jun23

Jun24

Jun25

Change In Receivables

Get a 7-Day Free Trial

-82.12

-1.63

29.39

-96.10

40.36

Human Metabolome Technologies Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26	Jun26
Change In Receivables	Get a 7-Day Free Trial															0.00	0.00	0.00	0.00	0.00

62GF Score

Human Metabolome Technologies Inc TSE:6090

Change In Receivables is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Start Your Free 7-Day GuruFocus Premium Trial

Unlock 30-Y financials, GF Score, and 150+ pro screeners →

Human Metabolome Technologies Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was 円0 Mil.

Frequently Asked Questions Learn more about Change In Receivables →

What does a Change In Receivables of 円0 Mil mean?

Human Metabolome Technologies (TSE:6090) has a Change In Receivables of 円0 Mil as of Mar. 2026. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for Human Metabolome Technologies and its competitors.

Is Human Metabolome Technologies' Change In Receivables too high?

Human Metabolome Technologies' current Change In Receivables is 円0 Mil. Overall, Human Metabolome Technologies has a GF Score™ of 62/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.

How does Human Metabolome Technologies' Change In Receivables compare to TMO and DHR?

Human Metabolome Technologies' Change In Receivables of 円0 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Change In Receivables for a Medical Diagnostics & Research company?

A good Change In Receivables depends on the Medical Diagnostics & Research industry context. However, Change In Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Change In Receivables mean?

A high Change In Receivables can signal that a stock is expensive relative to its fundamentals. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for Human Metabolome Technologies and its competitors. Human Metabolome Technologies's current Change In Receivables is 円0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Human Metabolome Technologies stock overvalued right now?

Based on GuruFocus' analysis, Human Metabolome Technologies (TSE:6090) is currently considered Modestly Undervalued. The stock's GF Value™ is 円695.84, compared to a current price of 円608.00 — trading 12.6% below its estimated fair value. The current Change In Receivables is 円0 Mil. Human Metabolome Technologies' overall GF Score™ is 62/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Change In Receivables calculated?

Change In Receivables is calculated from a company's financial statements. For Human Metabolome Technologies (TSE:6090), the current Change In Receivables is 円0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Human Metabolome Technologies (TSE:6090) Overvalued in 2026?

Based on GuruFocus' analysis, Human Metabolome Technologies stock appears to be undervalued. The current stock price of 円608.00 is trading 12.6% below its estimated GF Value™ of 円695.84. GuruFocus considers Human Metabolome Technologies to be Modestly Undervalued.

Key valuation signals for TSE:6090:

Change In Receivables: 円0 Mil
GF Value™: 円695.84 vs. price of 円608.00 (12.6% below fair value)
GF Score™: 62/100 with 3 warning signs

No single metric tells the full story. See the TSE:6090 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Start Your Free 7-Day GuruFocus Premium Trial

Unlock 30-Y financials, GF Score, and 150+ pro screeners →